» Articles » PMID: 20570629

IL-2-deprivation and TGF-beta Are Two Non-redundant Suppressor Mechanisms of CD4+CD25+ Regulatory T Cell Which Jointly Restrain CD4+CD25- Cell Activation

Overview
Journal Immunol Lett
Date 2010 Jun 24
PMID 20570629
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The benefits of immunotherapy by regulatory T (Treg) cells are unpredictable partially due to the uncertainty of their suppressive mechanism. In fact, various suppressive mechanisms have been proposed but each remains controversial. To better understand Treg-mediated suppression, we have investigated factors which may influence the suppressive effects. In an in vitro suppression assay, over-expression of anti-apoptotic Bcl2 enhancing survival of conventional T responder cells (Tconvs) did not subvert Treg-mediated suppression. In contrast, enhancing activation of Tconvs by increasing the potency of calcium signals completely abrogated Treg-mediated suppression. While Tregs were incapable of suppressing already activated Tconvs, they prevented expression of activation markers on naïve Tconvs during activation, thereby indicating that Tregs mediate suppression through controlling early activation stage. Interestingly, IL-2 deprivation or TGF-beta, two suppressive mechanisms, did not effectively inhibit Tconv activation and proliferation when applied alone. In contrast, IL-2 deprivation combined with TGF-beta suppressed Tconv activation as potently as Tregs. More importantly, in the transwell system, that separates Tregs from Tconvs, TGF-beta contributed to Treg suppression under IL-2 depriving condition. In conclusion, these two suppressive mechanisms acting in concert may be necessary to effectively restrain the early activation of Tconvs.

Citing Articles

Systems immunology of regulatory T cells: can one circuit explain it all?.

Tripathi S, Tsang J, Park K Trends Immunol. 2023; 44(10):766-781.

PMID: 37690962 PMC: 10543564. DOI: 10.1016/j.it.2023.08.007.


Inflammation, Immune Senescence, and Dysregulated Immune Regulation in the Elderly.

Shive C, Pandiyan P Front Aging. 2022; 3:840827.

PMID: 35821823 PMC: 9261323. DOI: 10.3389/fragi.2022.840827.


The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches.

Kanda N, Hoashi T, Saeki H J Clin Med. 2021; 10(17).

PMID: 34501328 PMC: 8432197. DOI: 10.3390/jcm10173880.


IL-1β-MyD88-mTOR Axis Promotes Immune-Protective IL-17AFoxp3 Cells During Mucosal Infection and Is Dysregulated With Aging.

Bhaskaran N, Faddoul F, Paes da Silva A, Jayaraman S, Schneider E, Mamileti P Front Immunol. 2020; 11:595936.

PMID: 33240286 PMC: 7677307. DOI: 10.3389/fimmu.2020.595936.


Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.

Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M Oncoimmunology. 2017; 6(8):e1338238.

PMID: 28920001 PMC: 5593706. DOI: 10.1080/2162402X.2017.1338238.


References
1.
Pesu M, Watford W, Wei L, Xu L, Fuss I, Strober W . T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature. 2008; 455(7210):246-50. PMC: 2758057. DOI: 10.1038/nature07210. View

2.
Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

3.
Malek T . The biology of interleukin-2. Annu Rev Immunol. 2007; 26:453-79. DOI: 10.1146/annurev.immunol.26.021607.090357. View

4.
Garin M, Chu C, Golshayan D, Cernuda-Morollon E, Wait R, Lechler R . Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2006; 109(5):2058-65. DOI: 10.1182/blood-2006-04-016451. View

5.
Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View